Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.50
+0.06 (+0.42%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...
Via
Benzinga
Exposures
Product Safety
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
August 07, 2024
Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this...
Via
Benzinga
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
August 07, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
July 31, 2024
Takeda Pharmaceutical just reported results for the first quarter of 2024.
Via
InvestorPlace
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
July 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.
Via
InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
July 24, 2024
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK...
Via
Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
July 09, 2024
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to...
Via
Benzinga
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
July 06, 2024
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was...
Via
Talk Markets
Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
July 02, 2024
Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020.
Via
Benzinga
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
June 28, 2024
Protagonist Therapeutics will join the SmallCap 600 on Wednesday.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Takeda Announces New Assignments of Directors
June 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
June 24, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
June 22, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
June 21, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
June 21, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 18, 2024
Via
Benzinga
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
June 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
June 17, 2024
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.
Via
Benzinga
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
June 17, 2024
Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes
Via
Benzinga
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
June 17, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
June 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
June 11, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 F-Rated Stocks to Avoid at All Costs in June
June 06, 2024
The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.
Via
InvestorPlace
Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
June 03, 2024
Blackstone reportedly considers sale of Japanese consumer healthcare firm Alinamin Pharmaceutical (previously owned by Takeda) for $1.9B, attracting interest from other firms.
Via
Benzinga
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
June 03, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
June 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.